Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

The present invention relates to sylvinite ore processing in the extraction industry and provides a resource-efficient method of separating potassium chloride and sodium chloride from polymineral sources comprising potassium chloride and sodium chloride and a vertical three-zone reactor for separating potassium chloride and sodium chloride from polymineral sources comprising potassium chloride and sodium chloride.

The present invention relates to a three-phase methodology to obtain a highly concentrated, purified chemical component from plant material in an industrial setting. The three phases of the methodology of the present invention include Phase 1: Preparing and solubilization, Phase 2: Separation and Salting and Phase 3: crystallization. The methodology results in dried composition purified from a plant material having at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the chemical component by weight.

Stable liquid formulations dominant in cannabidiol (CBD) can be manufactured by a sequential process of purification to create a formulation that does not crystallize under a variety of storage and use conditions, and without the use of potentially harmful additives. For example, the formulation may be used in vaporization devices (i.e., electronic cigarettes) that typically require formulations to remain in a non-crystalline, non-solid, or non-partially solid state. The liquid formulations dominant in CBD may further contain other phytocannabinoids, including, but not limited to, tetrahydrocannabinol (THC), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and cannabidivarin (CBDV) in higher concentrations than unrefined and refined cannabis extracts obtained via existing methods.

The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.

Treating brine to produce distilled water and dried NaCl. The brine enters a crystallization plant and is heated. Once heated, the brine is circulated to an evaporator. The evaporator increases the concentration of NaCl in the brine to a point about the super saturation level. Once above the super saturation level, NaCl crystals are formed. The larger crystals are circulated to a centrifuge for drying and the smaller crystals are recirculated through the evaporator for continued growth. The NaCl crystals are dried in the centrifuge.

The invention discloses a purification method, system and a detection method of N-methylmorpholine N-oxide (NMMO), and a N-methylmorpholine N-oxide obtained thereof. The NMMO is derived from a NMMO crude product prepared by the reaction of N-methylmorpholine with hydrogen peroxide. The mass concentration of NMMO in the NMMO crude product is 50% to 60%. The purification method includes: performing cooling crystallization to the NMMO crude product between ?20? C. and 78? C. to obtain crystalline NMMO. The NMMO purification method has a low cost, a high purity of the obtained NMMO product, and almost no generation of exhaust gas, waste water, and solid waste. Different from current NMMO purification process, the purification method of the invention does not require ion-exchange resin, thus completely solved problems of significant amount of wastewater with high concentration of salt and COD and spent ion-exchange resin caused by the regeneration of ion-exchange resin.

A method of making CBD concentrate or CBD Isolate comprises (a) milling a raw material; (b) contacting the milled raw material with an extraction solvent and separating a solid waste material to form a filtered extract; (c) concentrating the filtered extract; (d) washing the concentrated extract to form an organic phase and an aqueous phase; (e) separating the aqueous phase from the organic phase to form a washed extract; (f) removing an organic solvent from the washed extract to form a concentrated washed extract; (g) decarboxylating the concentrated washed extract; (h) vacuum distilling the decarboxylated extract to form a distillate; (i) dewaxing the distillate to form a post-dewax filtrate; (j) applying a vacuum to the post-dewax filtrate to form a post-dewax concentrate; (k) degassing the post-dewax concentrate; and (l) vacuum distilling the degassed concentrate to form a CBD concentrate.

Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

The invention relates to a process for purifying alkanesulfonic acids which comprises the steps of: (a) distilling a melt comprising crude alkanesulfonic acid (1) to completely or partly remove low boilers, wherein the low boilers are drawn off at the top of a distillation column (3) or of a one-stage evaporation apparatus and a material stream (7) comprising alkanesulfonic acid, high boilers and residual low boilers is withdrawn at the bottom of the distillation column (3) or of the one-stage evaporation apparatus, (b) sending the stream (7) comprising alkanesulfonic acid, high boilers and residual low boilers into a melt crystallization (9) as the starting melt to form crystals of the alkanesulfonic acid, of hydrates of the alkanesulfonic acid or of a mixture of both suspended in mother liquor, (c) performing a solid-liquid separation to remove the crystals from the mother liquor, (d) optionally washing the crystals to remove mother liquor adhering to the crystals.